{name}
{subtitle}
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~25 mi. (Yvoir, Belgium, +130 more cities)
facility
CHU UCL Namur Site de Godinne ( Site 0103)
drug
BCG solution, +1 more drug
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~25 mi. (Yvoir, Belgium, +207 more cities)
facility
CHU UCL Namur Site de Godinne ( Site 0706)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~25 mi. (Yvoir, Belgium, +159 more cities)
facility
CHU UCL Namur Site de Godinne ( Site 0354)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~25 mi. (Yvoir, Belgium, +122 more cities)
facility
CHU UCL Namur Site de Godinne ( Site 1004)
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma
city
~25 mi. (Yvoir, Belgium, +110 more cities)
facility
Centre Hospitalier Universitaire Universite Catholique de Louvain Site Godinne
drug
rituximab, +1 more drug
drug type
immunotherapy, +1 more type
Evaluation of Pembrolizumab (MK-3475) or Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
city
~25 mi. (Yvoir, Belgium, +30 more cities)
facility
Université Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 0102)
drug
MK-1308A, +4 more drugs
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
city
~25 mi. (Yvoir, Belgium, +45 more cities)
facility
CHU Mont-Godinne
condition
Multiple Myeloma, +2 more conditions
drug
CC-92480, +1 more drug
drug type
hormone therapy, +1 more type